Funding for this research was provided by:
Aarhus University (-)
Boehringer Ingelheim Denmark (-)
The Danish Lung Association’s Fund (-)
The Health Research Fund of the Central Denmark Region (-)
The Ellen and Knud Dalhoff Larsen’s Fund (-)
Received: 20 May 2019
Accepted: 20 August 2019
First Online: 28 August 2019
Ethics approval and consent to participate
: The study was approved by the Central Denmark Region Committee of Biomedical and Research Ethics (case no. 1–10–72-87-16) and the Danish Data Protection Agency, and it was registered at clinicaltrials.org (ExternalRef removed). The participants gave written and informed consent before participating in the study.
: Not applicable.
: JY developed the SGRQ-I and has nothing else to disclose. TSP, OH and EB have received an unrestricted grant from Boehringer Ingelheim for the current work. Outside the current work, TSP reports personal fees from Boehringer Ingelheim and Roche, NH reports and unrestricted grant from Roche, SBS reports personal fees from Boehringer Ingelheim, Roche and AstraZeneca, JRD reports an unrestricted grant from Boehringer Ingelheim and an unrestricted grant and personal fees from Roche, OH reports an unrestricted grant from Roche and an unrestricted grant and personal fees from Boehringer Ingelheim, EB reports unrestricted grants and personal fees from Boehringer Ingelheim, Roche, Novartis and AstraZeneca.